Pro Medicus stock reports 22.9 percent FY2026 revenue growth brings focus to valuation and execution

Published on 10/07/2026 at 06:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pro Medicus stock was trading at AUD 159.60 on October 7, 2026, against a market value of AUD 16.7 billion. FY2026 underlying profit rose 24.1 percent.

Pro Medicus, AU000000PME8, Illustration mit AI erstellt.

Pro Medicus stock was trading at AUD 159.60 on the ASX on October 7, 2026, while the company entered the new fiscal year after reporting AUD 261.7 million in FY2026 revenue. The result puts growth and valuation on the same page for investors assessing the medical imaging software provider.

FY2026 growth remains measurable

According to Motley Fool Australia, FY2026 revenue increased 22.9 percent from the prior corresponding period to AUD 261.7 million, while underlying net profit after tax rose 24.1 percent to AUD 144.7 million.

The same FY2026 report showed an underlying EBIT margin of 74.9 percent. Pro Medicus also signed 10 new contracts worth AUD 407 million and renewed six contracts on five-year terms worth AUD 141 million, giving the reported growth a multi-year commercial base.

Board change adds technology experience

MarketScreener reported that Tim Reed became an independent non-executive director on October 1, 2026. Reed previously led MYOB as chief executive from 2008 to 2019 and later worked in technology-focused private equity, adding software and governance experience to the board.

The next scheduled corporate checkpoint is the annual general meeting on November 25, 2026. The date is listed by Simply Wall St, giving shareholders a defined governance date after the FY2026 release.

Consensus target stays above price

The analyst consensus on the MarketScreener page is Outperform from 15 analysts, with an average target of AUD 202.47. That target lies 26.86 percent above the ASX price of AUD 159.60, while the same page lists a last close of AUD 161.31 and a consensus spread of 25.52 percent.

The distance between the market price and the consensus target makes execution important: the FY2026 figures provide the operating record, while the contract pipeline and upcoming AGM offer the next concrete points for assessing delivery.

Pro Medicus stock trades below yearly high

Pro Medicus stock was trading at AUD 159.60 on October 7, 2026 at 3:20 p.m. AEDT, with a session range of AUD 158.24 to AUD 161.66. Its 52-week range was AUD 107.75 to AUD 316.26, and its market capitalization was AUD 16.7 billion.